Is the revised pharmaceutical industry listed?

Revision Pharmaceutical Group is a large modern private pharmaceutical enterprise integrating medical research, production and marketing. Excellent Laigui was established in May 1995 and its headquarters is in Changchun.

The company's business includes Chinese patent medicine, chemical pharmacy, drug chain operation and large-scale cultivation of Chinese herbal medicines. In August 2004, the company acquired Jilin Shuangyang Sika Deer Group; In June 2004, the company changed its name to Pharmaceutical Industry Group. On September 10, 2020, the All-China Federation of Industry and Commerce announced the top 500 public and private enterprises in 2020, and revised the ranking of pharmaceutical industry groups to 124.

Judging from the current situation, the revised pharmaceutical industry is not listed and there is no corresponding stock code. Revised pharmaceutical industry has been trying to go public since 2003, but it has not passed the IPO so far.

The latest news is that the revision of Pharmaceutical Group Co., Ltd. or backdoor registration of Yaoji Holdings once caused heated discussion in the capital market.

However, on the evening of July 24th, 20021year, Yaoji Holdings announced that it would terminate the acquisition and modify the pharmaceutical industry. The announcement said: "After full argumentation by all parties, the current restructuring plan does not have the implementation conditions, and the continuous advancement of this major asset restructuring faces great uncertainty. After careful discussion, the company decided to terminate this major asset restructuring. "

At this point, the road to listing the revised pharmaceutical industry has once again been "stranded".

As of May 20th,19, 10, the revised pharmaceutical industry was not listed. Revised pharmaceutical industry has been trying to go public since 2003, but it has not passed the IPO so far. In order to go public, the company tried A shares, Hong Kong stocks, backdoor listing and so on, and finally failed.

20 17 Jilin province's judgment on amending the chairman of the pharmaceutical industry gave the market an explanation: the chairman of the enterprise paid bribes, which is also the reason why the enterprise chose to give up the IPO on its own.